If you have been reading about epitalon and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four amino acid residues |
| Residue sequence | Ala-Glu-Asp-Gly | Abbreviated AEDG |
| Approximate mass | 390.35 Da | Monoisotopic, free base form |
| Parent preparation | Epithalamin extract | Derived from pineal tissue |
| Common spelling variants | Epithalon, epithalone, AEDG | Affects literature retrieval |
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Although as of 2016, NEO212 has not been tested in humans, it has shown superior cancer therapeutic activity in animal models of glioma, melanoma, and brain metastasis of triple-negative breast cancer. Because tumor cells that express the O-6-methylguanine-DNA methyltransferase (MGMT) gene are more resistant to the effects of temozolomide, researchers investigated whether the inclusion of O6-benzylguanine (O6-BG), an AGT inhibitor, could overcome this resistance and improve the drug's therapeutic effectiveness. In the laboratory, this combination indeed showed increased temozolomide activity in tumor-cell culture in vitro and in animal models in vivo. However, a recently completed phase-II clinical trial with brain-tumor patients yielded mixed outcomes; while there was some improved therapeutic activity when O6-BG and temozolomide were given to patients with temozolomide-resistant anaplastic glioma, there seemed to be no significant restoration of temozolomide sensitivity in patients with temozolomide-resistant glioblastoma multiforme. Some efforts focus on engineering hematopoietic stem cells expressing the MGMT gene prior to transplanting them into brain-tumor patients. This would allow for the patients to receive stronger doses of temozolomide, since the patient's hematopoietic cells would be resistant to the drug. High doses of temozolomide in high-grade gliomas have low toxicity, but the results are comparable to the standard doses.
== Mechanism of action == Telithromycin prevents bacteria from growing, by interfering with their protein synthesis. Telithromycin binds to the subunit 50S of the bacterial ribosome, and blocks the progression of the growing polypeptide chain. Telithromycin has over 10 times higher affinity to the subunit 50S than erythromycin. In addition, telithromycin strongly bind simultaneously to two domains of 23S RNA of the 50 S ribosomal subunit, where older macrolides bind strongly only to one domain and weakly to the second domain. Like many other protein synthesis inhibitors, telithromycin can also inhibit the formation of ribosomal subunits 50S and 30S.
== Prevention == Methods in preventing amputation, limb-sparing techniques, depend on the problems that might cause amputations to be necessary. Chronic infections, often caused by diabetes or decubitus ulcers in bedridden patients, are common causes of infections that lead to gangrene, which, when widespread, necessitates amputation. There are two key challenges: first, many patients have impaired circulation in their extremities, and second, they have difficulty curing infections in limbs with poor blood circulation. Crush injuries where there is extensive tissue damage and poor circulation also benefit from hyperbaric oxygen therapy (HBOT). The high level of oxygenation and revascularization speed up recovery times and prevent infections. A study found that the patented method called Circulator Boot achieved significant results in prevention of amputation in patients with diabetes and arteriosclerosis. Another study found it also effective for healing limb ulcers caused by peripheral vascular disease. The boot checks the heart rhythm and compresses the limb between heartbeats; the compression helps cure the wounds in the walls of veins and arteries, and helps to push the blood back to the heart. For victims of trauma, advances in microsurgery in the 1970s have made replantation of severed body parts possible. The establishment of laws, rules, and guidelines, and the employment of modern equipment help protect people from traumatic amputations.
Gabapentin enacarbil, sold under the brand name Horizant, among others, is an anticonvulsant and analgesic drug of the gabapentinoid class, and a prodrug to gabapentin. It was designed for increased oral bioavailability over gabapentin, and human trials showed it to produce extended release of gabapentin with almost twice the overall bioavailability, especially when taken with a fatty meal. Gabapentin enacarbil has passed human clinical trials for the treatment of restless legs syndrome, and initial results have shown it to be well tolerated and reasonably effective. Gabapentin enacarbil was denied approval by the US Food and Drug Administration (FDA) in February 2010, citing concerns about possible increased cancer risk shown by some animal studies. Similar concerns had been raised about gabapentin itself in the past, but were felt to be outweighed by its clinical utility as an anticonvulsant, whereas the treatment of restless legs syndrome was not seen to justify the same kind of risk. On 6 April 2011, Xenoport received FDA approval for Horizant (gabapentin enacarbil) for the treatment of moderate-to-severe restless legs syndrome. On 7 June 2012, the FDA approved Horizant for the treatment of postherpetic neuralgia in adults.
Sources: en.wikipedia.org
== Receptor regulation == Cells can increase (upregulate) or decrease (downregulate) the number of receptors to a given hormone or neurotransmitter to alter their sensitivity to different molecules. This is a locally acting feedback mechanism.
Hastert entered Congress in 1987 with a net worth of no more than $270,000. At the time, his most valuable asset was a 104-acre farm in southern Illinois (which his wife had inherited), worth between $50,000 and $100,000. When Hastert left Congress twenty years later, he reported a significantly increased net worth, variously reported as between $4 million and $17 million and between $3.1 million and $11.3 million. Much of this increase in net worth was the result of various real-estate investments during Hastert's time in Congress (including the controversial land deal several miles from the proposed Prairie Parkway site). At the time Hastert left Congress, much of his net worth remained tied up in real-estate holdings. State Senator Chris Lauzen, Geneva Mayor Kevin Burns, and wealthy dairy businessman Jim Oberweis all entered the campaign for the Republican nomination to succeed Hastert. In December 2007, Hastert endorsed Oberweis in the primary, and Burns withdrew from the race. In the contentious February 2008 primary election, Oberweis was chosen as the Republican nominee, and Fermilab scientist Bill Foster was selected as the Democratic nominee. In the special election in March 2008 to fill the rest of Hastert's unexpired term, Foster won a surprise victory over Oberweis. In a rematch in the November 2008 elections for a full two-year term, Foster again defeated Oberweis.
In order for a protonated acid to lose a proton, the pH of the system must rise above the pKa of the acid. The decreased concentration of H+ in that basic solution shifts the equilibrium towards the conjugate base form (the deprotonated form of the acid). In lower-pH (more acidic) solutions, there is a high enough H+ concentration in the solution to cause the acid to remain in its protonated form. Solutions of weak acids and salts of their conjugate bases form buffer solutions. To determine the concentration of an acid in an aqueous solution, an acid–base titration is commonly performed. A strong base solution with a known concentration, usually NaOH or KOH, is added to neutralize the acid solution according to the color change of the indicator with the amount of base added. The titration curve of an acid titrated by a base has two axes, with the base volume on the x-axis and the solution's pH value on the y-axis. The pH of the solution always goes up as the base is added to the solution.
CDs and DVDs have a polycarbonate surface and metal reflective layer which allow for storage and retrieval of information. The metal film is sometimes made of pure gold which is highly stable and has ideal optical properties. The metal can act as a substrate which allows compounds to bind to it. This alters the reflective and refractive properties of the disk. Disk reading is based on capturing analog signals with the disk drive. The signals are indicative of how much analyte is in a sample. Because the disk spins, the platform has the ability to drive the sample through it through microfluidic channels and for multiple steps to be performed, allowing the possibility for sample preparation and more than one analysis to be conducted during a single run. CD/DVD based assays could potentially be used for any immunoassay already in use and many assays used in analytical chemistry, as long as analytes have a corresponding probe, are soluble, and are large enough to alter the angle of incident.
Researchers in the field have developed approaches to produce living organs that are constructed with the appropriate biological and mechanical properties. 3D bioprinting is based on three main approaches: biomimicry, autonomous self-assembly and mini-tissue building blocks. The first approach of bioprinting is called biomimicry. The main goal of this approach is to create fabricated structures that are identical to the natural structure that are found in the tissues and organs in the human body. Biomimicry requires duplication of the shape, framework, and the microenvironment of the organs and tissues. The application of biomimicry in bioprinting involves creating both identical cellular and extracellular parts of organs. For this approach to be successful, the tissues must be replicated on a micro scale. Therefore, it is necessary to understand the microenvironment, the nature of the biological forces in this microenvironment, the precise organization of functional and supporting cell types, solubility factors, and the composition of extracellular matrix.
Sources: en.wikipedia.org
=== Elderly === For the elderly, benzodiazepines have reduced benefits and increased risks. They are listed as a potentially inappropriate medication for older adults by the American Geriatrics Society. The elderly are at an increased risk of dependence and are more sensitive to the adverse effects such as memory problems, daytime sedation, impaired motor coordination, and increased risk of motor vehicle accidents and falls, and an increased risk of hip fractures. The long-term effects of benzodiazepines and benzodiazepine dependence in the elderly can resemble dementia, depression, or anxiety syndromes, and progressively worsens over time. Adverse effects on cognition can be mistaken for the effects of old age. The benefits of withdrawal include improved cognition, alertness, mobility, reduced risk of incontinence, and a reduced risk of falls and fractures. The success of gradual-tapering benzodiazepines is as great in the elderly as in younger people. Benzodiazepines should be prescribed to the elderly only with caution and only for a short period at low doses. Short to intermediate-acting benzodiazepines are preferred in the elderly such as oxazepam and temazepam. The high potency benzodiazepines alprazolam and triazolam and long-acting benzodiazepines are not recommended in the elderly due to increased adverse effects. Nonbenzodiazepines such as zaleplon and zolpidem and low doses of sedating antidepressants are sometimes used as alternatives to benzodiazepines.
Of the subjects who were administered Tepezza, 71% in study 1 and 83% in study 2 demonstrated a greater than 2 mm reduction in proptosis (eye protrusion) as compared to 20% and 10% of subjects who received placebo, respectively. The trials were conducted at 28 sites in Europe and United States. Teprotumumab-trbw was approved for use in the United States in January 2020, for the treatment of adults with thyroid eye disease. The FDA granted the application for teprotumumab-trbw fast-track, breakthrough therapy, priority review, and orphan drug designations. The FDA granted the approval of Tepezza to Horizon Therapeutics Ireland DAC.
Sucre wanted to delay any union of Bolivia with Peru as long as possible (knowing that it would fall under the latter's hegemony when it passed, weakening his government), annex all the territories offered by Ortiz, confront Colombia with Peru, secure his back by agreeing with Chile and Buenos Aires, and separate Arequipa, Cuzco and Puno from Peru. All this is demonstrated when Sucre indicated to Ortiz de Zevallos that: "only under that plan could Bolivia not fear that Peru would absorb it, as happens when a small State links up with a larger and stronger one". As well as when in 1827, Sucre appointed dean Gregorio Funes, a Bolivarian Argentine, who was carrying out the functions of Colombian minister in Buenos Aires, to receive the post of Bolivian minister in the same Argentine capital. Through Funes, Sucre addressed the issue of an alliance between Bolivia, Argentina and Chile, which was supposedly to stop Brazilian expansionism, but in practice he was looking for support against Peru because he knew its weakness against it, and suggested that the participation of Gran Colombia in the war against Brazil could occur through a treaty. From Santiago de Chile, Andrés Santa Cruz interpreted Sucre's opening to Buenos Aires as an attempt to form "an anti-popular and very particularly anti-Peruvian pact." The negotiations did not prosper because the Peruvians also sent agents who assured that Bolívar intended to divide the continent between two great empires: one Colombian and the other Brazilian.
== Measurement == An SaO2 (arterial oxygen saturation, as determined by an arterial blood gas test) value below 90% indicates hypoxemia (which can also be caused by anemia). Hypoxemia due to low SaO2 is indicated by cyanosis. Oxygen saturation can be measured in different tissues:
==== Optical peptide biosensors ==== In optical peptide biosensors, peptide-analyte binding events is converted into measurable optical changes. This depends on changes in fluorescence, luminescence, or absorbance upon analyte binding. The peptide sequence may be fluorescently labeled or monitored label-free through shifts in refractive index or optical density.
Sources: en.wikipedia.org
It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.
No. Epithalamin is a heterogeneous extract containing many peptides, while epitalon is a single synthesised tetrapeptide. Publications sometimes treat findings from the two as equivalent, which is a common source of confusion. Their compositions differ and they are not interchangeable in analytical terms.
Most published work uses cell cultures or rodents because those models are faster and less costly to run. The few human trials that have been reported are small, and several lack control groups or blinding. This restricts what can reasonably be concluded about effects in people.
It is a synthetic tetrapeptide. Its sequence was derived from research on peptide fractions of bovine pineal extract, and the intact AEDG sequence has not been demonstrated as an abundant free peptide in human tissue.